阻断血小板糖蛋白VI （GPVI）作为一种有前途的抗血栓治疗方法。

IF 7.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2025-09-10 DOI:10.1016/j.drudis.2025.104473

Ruofei Li , Zhiwei Qiu , Yimin Cui , Qian Xiang

{"title":"阻断血小板糖蛋白VI （GPVI）作为一种有前途的抗血栓治疗方法。","authors":"Ruofei Li , Zhiwei Qiu , Yimin Cui , Qian Xiang","doi":"10.1016/j.drudis.2025.104473","DOIUrl":null,"url":null,"abstract":"<div><div>Glycoprotein VI (GPVI), a key platelet receptor, mediates collagen-induced platelet activation and interacts with fibrin to promote thrombus growth. Studies demonstrate the mechanisms of GPVI in thrombosis, showing its inhibition reduces thrombosis without impairing hemostasis, consistent with the mild bleeding phenotype in GPVI-deficient individuals. GPVI is also implicated in inflammation and cancer. This review introduces the mechanism of GPVI in thrombosis and highlights two investigational GPVI-targeting drugs (glenzocimab and Revacept), summarizing current evidence and future directions for this promising antithrombotic approach.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104473"},"PeriodicalIF":7.5000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Blocking platelet glycoprotein VI (GPVI) as a promising antithrombotic treatment\",\"authors\":\"Ruofei Li , Zhiwei Qiu , Yimin Cui , Qian Xiang\",\"doi\":\"10.1016/j.drudis.2025.104473\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Glycoprotein VI (GPVI), a key platelet receptor, mediates collagen-induced platelet activation and interacts with fibrin to promote thrombus growth. Studies demonstrate the mechanisms of GPVI in thrombosis, showing its inhibition reduces thrombosis without impairing hemostasis, consistent with the mild bleeding phenotype in GPVI-deficient individuals. GPVI is also implicated in inflammation and cancer. This review introduces the mechanism of GPVI in thrombosis and highlights two investigational GPVI-targeting drugs (glenzocimab and Revacept), summarizing current evidence and future directions for this promising antithrombotic approach.</div></div>\",\"PeriodicalId\":301,\"journal\":{\"name\":\"Drug Discovery Today\",\"volume\":\"30 10\",\"pages\":\"Article 104473\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359644625001862\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644625001862","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

糖蛋白VI （GPVI）是一种关键的血小板受体，介导胶原诱导的血小板活化并与纤维蛋白相互作用，促进血栓的生长。研究证实了GPVI在血栓形成中的作用机制，其抑制作用在不影响止血的情况下减少血栓形成，这与GPVI缺乏个体的轻度出血表型一致。GPVI还与炎症和癌症有关。本文介绍了GPVI在血栓形成中的作用机制，重点介绍了两种正在研究的GPVI靶向药物（glenzocimab和Revacept），总结了这种新型抗血栓方法的现有证据和未来发展方向。glenzocimab和Revacept等抑制剂对糖蛋白VI （GPVI）的靶向治疗。该图总结了从临床前证据（在不增加出血风险的情况下确定了抗血栓疗效）到正在进行的临床评估（包括急性缺血性卒中、心肌梗死、COVID-19和症状性颈动脉狭窄）的转变。这个图形是用BioRender创建的。导读：本文综述了GPVI在血栓形成、炎症和癌症中的多重作用，同时总结了GPVI靶向药物开发的最新进展，为相关疾病的治疗干预提供了新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Blocking platelet glycoprotein VI (GPVI) as a promising antithrombotic treatment

查看原文本刊更多论文

Blocking platelet glycoprotein VI (GPVI) as a promising antithrombotic treatment

Glycoprotein VI (GPVI), a key platelet receptor, mediates collagen-induced platelet activation and interacts with fibrin to promote thrombus growth. Studies demonstrate the mechanisms of GPVI in thrombosis, showing its inhibition reduces thrombosis without impairing hemostasis, consistent with the mild bleeding phenotype in GPVI-deficient individuals. GPVI is also implicated in inflammation and cancer. This review introduces the mechanism of GPVI in thrombosis and highlights two investigational GPVI-targeting drugs (glenzocimab and Revacept), summarizing current evidence and future directions for this promising antithrombotic approach.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.